Table 3 Univariate analysis
From: Bendamustine in patients with relapsed or refractory multiple myeloma
| Â | EFS | OS |
|---|---|---|
ISS stage (I vs. II+II) | 0.2 | 0.001 |
Cytogenetics (normal vs. abnormal karyotype) | 0.05 | 0.2 |
LDH (</> 200 U/l) | 0.5 | 0.02 |
CRP (</> 0.6 mg/dl) | 0.7 | 0.001 |
Haemoglobine level (</> 10 g/dl) | 0.2 | 0.04 |
Platelet count (</> 200.000/ÎĽl) | 0.6 | 0.1 |
Chemosensitivity (relapse vs. refractory) | 0.4 | 0.01 |
Prior thalidomide | 0.4 | 1.0 |
Prior high-dose therapy | 0.5 | 0.4 |
Extramedullary manifestation | 0.4 | 0.2 |
Osteolytic lesions | 0.5 | 0.3 |
Bendamustine dosage </> 120 mg/m2 | 0.6 | 0.9 |
Monotherapy vs. Steroid combination therapy | 0.7 | 0.3 |